
Decoy Therapy Reverses Mitochondrial Failure in Parkinson's Models
Scientists show that alpha-synuclein directly binds the ClpP enzyme, sabotaging mitochondria and fueling neuron loss in Parkinson's models; they created CS2, a decoy that blocks this interaction, restoring mitochondrial function, reducing inflammation, and improving movement and cognition in tissue and animal models, with plans to advance toward human trials.





